New to peptides? Start with the foundations ->
The dad-test answer
Sermorelin is the older GHRH (1-29) fragment, FDA-approved in 1990 for growth hormone deficiency before being voluntarily withdrawn for non-safety commercial reasons. CJC-1295 is the modern biohacker version - same 29-amino-acid backbone, modified to extend half-life. Sermorelin gives you cleaner pulsatile GH release; CJC-1295 (no DAC) is more potent and is the molecule operators stack with ipamorelin. CJC-1295 is the better choice for most operators in 2026; sermorelin is still legitimate, just dated.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| regulatory history, prior FDA approval |
sermorelin FDA-approved 1990 (Geref) for diagnostic and pediatric GHD use; withdrawn for commercial reasons not safety - CJC-1295 has never had FDA review. |
| potency at the GHRH receptor |
cjc-1295 Lysine modifications give CJC-1295 longer half-life and higher receptor occupancy than native GHRH (1-29) / sermorelin. |
| natural pulsatile GH release |
sermorelin Short half-life (~10-20 minutes) preserves the body's pulsatile GH pattern most cleanly. |
| stacking with ipamorelin |
cjc-1295 CJC-1295 + ipamorelin is the standard biohacker GH-axis stack; sermorelin + ipamorelin is workable but less common in modern protocols. |
What the head-to-head data shows
Sermorelin is the natural GHRH (1-29) fragment - the shortest active GHRH sequence. The FDA approved it as Geref in 1990 for diagnostic GHD testing and in 1997 for pediatric GHD therapy; manufacturer EMD Serono voluntarily withdrew the brand in 2008 for commercial reasons unrelated to safety. Sermorelin has a half-life of about 10-20 minutes and is sold by US compounding pharmacies under prescription. CJC-1295 is the same 29-amino-acid backbone with lysine modifications that resist DPP-IV degradation; Teichman et al. 2006 characterized CJC-1295's pharmacokinetics in healthy adults. Without the DAC modification, CJC-1295's half-life is roughly 30 minutes - longer than sermorelin and pulsatile enough to preserve physiologic GH release. The mechanistic basis for both molecules sits in the broader GH secretagogue literature - Sigalos and Pastuszak 2018 reviews the safety and efficacy of GHRH analogs and ghrelin agonists across the category. Both molecules have an ideal use case in adults seeking GH-axis support without exogenous HGH; neither has the extensive Phase 3 trial record of tesamorelin (the FDA-approved GHRH analog for HIV lipodystrophy).
Our honest call
For most operators in 2026, CJC-1295 (no DAC) is the better choice - it's more potent at the GHRH receptor, half-life is long enough to dose once daily before bed without losing pulsatility, and it stacks cleanly with ipamorelin in the standard biohacker protocol. Sermorelin is still legitimate medicine - decades of safety data, prior FDA approval, and a clean mechanism - but it's effectively the old version of the same molecule. The reasonable case for sermorelin: a clinician comfortable with the pre-2008 prescribing record, or an adherence-limited user who only wants to handle one peptide in the syringe. The reasonable case for CJC-1295: anyone running the GH-axis stack with ipamorelin - that's the standard protocol most clinics offer in 2026. Read the CJC-1295 dosing breakdown.
Sources and citations
- Teichman et al., CJC-1295 pharmacokinetics in healthy adults, J Clin Endocrinol Metab 2006 (PMID 16352683)
- FDA Geref (sermorelin) prescribing label (approved 1990, withdrawn 2008 for commercial reasons)
- Sigalos and Pastuszak, GH secretagogue review, Sex Med Rev 2018
- Walker, Sermorelin: a better approach to GH replacement, Endocr Rev 2006
- US compounding pharmacy formularies
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.